I believe that SI is the one who inferred that after the phase 3 trial failed to meet the primary end point. The the patients needed to be dosed early to be most effective.
He said the same thing about CHF and when it's the best time to administer the cells; that is as early as possible too.
You are probably confused because at one stage SI did say the cells were most effective for the sickest of the sick (phase 2 results), but then the latest updates (phase 3 results) he has said otherwise.
MSB Trading 2021 - paradigm shift, page-229
-
- There are more pages in this discussion • 9,982 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |